/CNW/ -- USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer...
VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before....
Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead...
Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) yesterday and set a price target of $37.00. The company's shares closed last Tuesday at $15.97....
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $54.00. The company's shares closed last Friday at $17.71....
SAN FRANCISCO, July 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...
SAN FRANCISCO, July 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...
NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial First patient dosed in NX-5948 Phase 1a clinical trial for certain...
NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumor types Phase 1 clinical trial now enrolling patients...
Posters provide background information and trial designs for ongoing clinical studies of wholly-owned NX-2127 and NX-5948 programs...